Quick Facts
  • Primary Location:
    Ochsner Medical Center
  • Expertise:
    Immunotherapy
    Precision Therapy
    Chemotherapy
  • Speciality:
    Medical Oncology
  • Gender:
    Male
  • Language:
    English
  • Med School:
    Louisiana State University New Orleans School of Medicine

Get to Know Dr. Daniel Johnson

Dr. Daniel Johnson is a medical oncologist and clinical investigator at Ochsner Medical Center in New Orleans. He treats lung cancer and malignant pleural mesothelioma, often utilizing novel immunotherapy.

Johnson and the specialists at Ochsner have helped advance the growing use of immunotherapy by developing strategies to overcome resistance to the treatment and prevent resulting toxicities.

As deputy director of medical oncology for the Precision Cancer Therapies Program, his research often focuses on designing and implementing clinical trials, several of which now involve immunotherapy and thoracic disease.

“Immunotherapy has changed the fight against cancer,” Johnson said. “Patients who come in feeling hopeless with very advanced disease should know there is hope out there with immunotherapy.”

Johnson, who has been lauded for his personalized approach to care, has spent much of his life in the New Orleans area, returning there after his fellowship at the University of Texas MD Anderson Cancer Center.

Contact Daniel Johnson
By submitting, you agree to our privacy policy and disclaimer. Our Patient Advocates may contact you via phone, email and/or text.

Specialties of Dr. Daniel Johnson

  • Immunotherapy
  • Targeted therapy
  • Lung cancer
  • Pleural mesothelioma
  • Head and neck medical oncology
  • Melanoma
  • Thymoma
  • Clinical trials

Dr. Daniel Johnson’s Experience and Education

  • Ochsner Medical Center
  • University of Texas MD Anderson Cancer Center (Fellowship)
  • LSU Health Sciences Center (Residency and internship)
  • LSU New Orleans School of Medicine (M.D.)

Awards and Certifications

  • American Board of Internal Medicine
  • Healthgrades Honor Roll

Publications of Dr. Daniel Johnson

  • Maslov, D.V. et al. (2021, May 17). Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer. Journal for ImmunoTherapy of Cancer.
  • Safa, H. et al. (2019, November 21). Immune checkpoint inhibitor related myasthenia gravis: single center experience and systemic review of the literature. Journal for Immunotherapy of Cancer.
  • Abdel-Wahab, N. et al. (2019, April 16). Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systemic review of the literature. Journal for ImmunoTherapy of Cancer.
  • Kim, S.K. et al. (2017, August 22). Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals of the Rheumatic Diseases.
man and his wife looking at computer together watching webinar from the mesothelioma center
Browse Our Free Mesothelioma Webinars
Access More than $32 Billion in Trust Funds
Scientist is laboratory studying cells under a microscope
Find Active Mesothelioma Clinical Trials